Mirwais Wardak

[Mirwais Wardak @DataDrivenPhD]

🚀Excited to co-chair a session with @Novartis and @Certara at #ACoP2025 in Aurora, CO!

🎯Advances in Mathematical & Computational Modeling for Radiopharmaceutical Therapies
🗓 Oct 21 | ⏰ 9–10 AM MDT | 📍 Red Rock 8/9

Hear from top experts in academia & industry—don’t miss it!

[Eric Topol @EricTopol]

Big progress vs cancer, folks.
The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO

[SNMMI @SNM_MI]

SOFIE Biosciences President, CEO, and Co-Founder Patrick Phelps talks with SNMMI TV about their company and its impact on the nuclear medicine field.
Video sponsored by @sofiebio: https://t.co/1NnYdbELaT

[Michael Hofman @DrMHofman]

This is @SNM_MI #SNMMI26
Not to be confused with @ASCO #ASCO26

[SNMMI @SNM_MI]

The plenary went live, the Exhibit Hall is open, and members and attendees from around the world have gathered in Los Angeles for the 2026 SNMMI Annual Meeting. Enjoy a quick recap of the day:

[SNMMI @SNM_MI]

Simon Cherry opens the plenary with an overview of the power and potential of nuclear medicine.

[CA: A Cancer Journal for Clinicians @CACancerJournal]

See @Dr_R_Kurzrock's poster at #ASCO26 on target-specific therapy for actionable & approved tumor-agnostic biomarkers. Read her #OpenAccess article on the evolving landscape of tissue-agnostic therapies in precision oncology published in CA.

https://t.co/Y8KMxoMPkG

@OncoAlert

[Michael Hofman @DrMHofman]

10 years ago there may have been zero or maybe one ☢️ nuclear medicine abstracts at @ASCO. Theranostics is now🔥.

This year, ~90 presentations and a dedicated oral session.

For those attending @SNM_MI , we are doing a live cross with @HJacene . Mon June 1, 2026 4:45 PM room 515A

[Stanford Department of Medicine @StanfordDeptMed]

In a new @ScienceMagazine study, #StanDOM researchers & collaborators at @harvardmed and @BIDMChealth found #OpenAI's o1 model outperformed physicians in diagnosis & management across real-world clinical scenarios. #HealthAI https://t.co/YVGC463kfM

[Eric Topol @EricTopol]

The p-tau217 breakthrough blood test replicated again, predicting Alzheimer's disease in a large cohort mean age 61. The cover of the new issue is telling @TheLancet https://t.co/Qre6mCkpMV

[nature @Nature]

Nature research paper: Universal transcriptomic hallmarks of mammalian ageing and mortality

https://t.co/9IbuF2tK5H

[UCLA @UCLA]

UCLA has opened the Center for Advanced Biotherapies, a new 14,000-square-foot facility that nearly doubles its capacity to develop and deliver personalized cell and gene therapies to patients. https://t.co/BTh5JPW4xi

[Ria Kraft, MD @riakraftmd]

It’s #radonc away rotation season! For #medstudents and junior #residents, here are my go-to resources in radiation oncology (1/2).

[ISoP @ISOP1]

Next ISoP MIDD Series Webinar

Beyond the Simulation: Embedding MIDD into Strategic Drug Development

🗓️ Wed June 24, 2026 | ⏰ 12–1 PM ET

🎤 Speaker: Jane Knöchel | Assistant Professor at the University of Copenhagen

🔗 Register | https://t.co/seKXAkZSMK

#ISoP #MIDD

[Eric Topol @EricTopol]

Cardiac "remuscularization" for treating severe heart failure with patched heart muscle derived from stem cells (a biological ventricular assist device) successful in 12 of 20 patients @NEJM
https://t.co/mAwgj2rAwE https://t.co/3ogxaJFDE0

[Jame Abraham, MD, FACP @jamecancerdoc]

Cellular Therapies in Solid Tumors: Are We Ready for Primetime? | JCO Oncology Practice https://t.co/IHI1eOCC11 @JCOOP_ASCO @ASCO @OncoAlert @JCO_ASCO

[Henry Han @HanCardiomd]

What is the #cardiologist of the future?

https://t.co/R5KHBUu1j6
#AI #Futuristic

@ESC_President @ESC_Journals #EHJ

[Max Marchione @maxmarchione]

In some very real sense, Ozempic was invented in 1990. Pfizer ran the human trials and just never published them.

They showed it lowered blood glucose in diabetics, slowed gastric emptying, and killed hunger; the same 3 things that make Ozempic work today.

The joint venture agreement said internal data stayed internal, and that was that. Pfizer killed the program in 1991. The reasoning, as far as I can tell, was that nobody would ever want an injectable diabetes drug besides insulin.

So, the license went back to the hospital in Boston that held the patents.

Novo picked it up in 1992 and spent the next two decades building liraglutide, then semaglutide.

It's insane that data sat in a filing cabinet for 30+ years.

I only know this because Jeffrey Flier, one of the Harvard scientists in the room, finally wrote it up. He's in his late 70s and didn't want the history to die with him.

This makes you wonder what else is in those filing cabinets.

Ozempic could've existed 27 years ago.

[Michael Hofman @DrMHofman]

Quantitative PET as a Catalyst for Precision Oncology

It was a real honour to present the 2026 Lowenthal Plenary Lecture at the #ANZSNM Annual Scientific Meeting.

The theme of this lecture is that precision oncology needs more than just better pictures. It needs us to measure biology - and we can do that with the PET-CT device in an extraordinary way.

From quantifying total tumour burden, to measuring organ function, to guiding personalised radioligand therapy dosing - quantitative PET is transforming how we understand and treat cancer.

🎯 Better measurements → better decisions → better outcomes for patients.

You can watch the full talk here: https://t.co/6iMdztaE0g

@anzsnm1969 @TheranosticsAus @pros_tic

[San Francisco Chronicle @sfchronicle]

Santa Clara University and Sutter Health plan to open the Bay Area’s first new medical school in more than 100 years, backed by a $175 million gift. https://t.co/2MAkJnXkhq

[The Wall Street Journal @WSJ]

Measuring cholesterol levels has long been the main way doctors assess the risk of heart disease. Increasingly, people are opting, too, for a simple, relatively affordable test: a coronary artery calcium scan.

Here’s more to know about the scans: 🔗 https://t.co/OP7gpJ9uvb